Valeant Pharmaceuticals International has sealed a definitive agreement for the acquisition of Bausch+Lomb for $8.7 billion. The Candian company will pay $4.5 billion in cash to the current owners, an investor group headed by the private equity firm Warburg Pincus, and another $4.2 billion in cash to reduce Bausch+Lomb's current ...
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
Or sign-up for a trial month for just 9,90€. To continue reading this article register now.